Market Overview

Mallinckrodt Spikes On Citron Tweet

Related VRX
TD Ameritrade Index Indicates Retail Investors Are At Their Most Bullish Point Yet
Investor Movement Index December Summary
Big Biopharma in the red in early trade (Seeking Alpha)
32 Biggest Movers From Yesterday
Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
De-Risking Catalysts Aplenty - Cara Therapeutics (Seeking Alpha)

Mallinckrodt PLC (NYSE: MNK) is up roughly 4 percent at $54.80 on Friday.

Contributing to the spike is a tweet from Citron Research, which read: "Clarification: Citron does not recommend short $MNK at $54 for short-term. Wait for fundamentals to ‘kick in' and guide lower –like $VRX."

This is not the first time the stock has moved on Citron news.

Related Link: Citron: Mallinckrodt Makes Valeant Look Like Choirboys

Earlier in the week, an article from The Street cited Citron's Andrew Left commenting on Mallinckrodt and Valeant Pharmaceuticals Intl Inc (NYSE: VRX). According to the article, the analyst called Mallinckrodt the "poster child" for price gouging and stated, "Mallinckrodt is squeaking by without anyone talking about it. Mallinckrodt makes Valeant look like a bunch of choirboys."

Subsequently, Mallinckrodt fell subject to a related selloff.

Posted-In: Andrew Left CitronLong Ideas News Short Ideas Movers Trading Ideas


Related Articles (VRX + MNK)

View Comments and Join the Discussion!